RxDoctor Payments Data

Quan Bui

Cardiovascular Disease · San Diego, CANPI 1831553718

Payments from drug & device makers

$117,251in general payments, 2019–2025

Across 108 payments — averaging $1085.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eidos Therapeutics, Inc.$53K
  • Astrazeneca UK Limited$43K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Bayer$6K
  • Baxter Healthcare$2K
  • Abiomed$1K
  • plus $3K from 15 others

What the payments were for

  • Consulting fees$13,85666%
  • Travel & lodging$1,2086%
  • Food & beverage$5,69627%
  • Education$2451%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,251 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$108,932
Medicare patients
276
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten16$132,383
JardianceEmpagliflozin57$60,685
EliquisApixaban46$48,553
EntrestoSacubitril/Valsartan42$41,491
FarxigaDapagliflozin Propanediol29$15,928
Repatha SureclickEvolocumab24$14,595
OzempicSemaglutide14$12,640
Mycophenolic AcidMycophenolate Sodium11$3,642
Tacrolimus12$2,524
Valganciclovir Hcl15$1,817
Nifedipine ErNifedipine26$1,564
Metoprolol Succinate79$1,229
Bumetanide37$1,199
Potassium Chloride16$1,114
Rosuvastatin Calcium89$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$8,562$132,38316 claims
PfizerEliquis$69$48,55346 claims
AstraZenecaFarxiga$131$15,92829 claims
Novo NordiskOzempic$619$12,64014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →